PTOSBS (04.07)
Approved for use through 03/3/2/007, OMB 0851-2/019
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Pagement Reduction Act of 1995, no persons are regulated to respond to a coloris

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE" APPLICATION	12810-00215-US1
In re Application of: Randolf Hugo et al.	
Application No.: 10/571,584-Conf. #9853	
Filed: March 10, 2006	
For: METHOD FOR PRODUCING XYLYLENEDIAMINE (XDA)	
The owner*. BASF Aktiengesellschaft	of 100
The owner*, BASF Aktiengesellschaft  percent interest in the instant application hereby disclaims, except as provided below, the termin	
any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any	
	March 10, 2006 , and ebruary 28, 2006
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on s	
be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner	
hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on	
the instant application and is binding upon the grantee, its successors or assigns.	a.y paran granta an
In making the above disclaimer, the owner does not disclaim the terminal part of any	natent granted on the instant
application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent	
granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filled prior to the grant of any patent on the pending reference application," in the event that; any such	
patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is	
found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration	
of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and helief are believed to be true; and further that these statements were made with the knowledge that willful false statements and he like so made are punishable by five or imprisoment; or both, under Section 1001 of Tille 16 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
The undersigned is an attorney or agent of record. Reg. No. 49,073	
43,073	
/Bryant L. Young/	March 12, 2009
Signature	Date
Bryant L. Young	
Typed or printed name	
	(202) 331-7111
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	
3	